Loading...
•
Jun 30, 2022
Dyne Therapeutics Q2 2022 Earnings Report
Reported financial results for the second quarter of 2022 and business highlights.
Key Takeaways
Dyne Therapeutics reported a net loss of $52.3 million for the second quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $291.8 million as of June 30, 2022, which is anticipated to fund operations into the second half of 2024. They are on track for mid-2022 for initiation of patient dosing in multiple ascending dose clinical trials for DYNE-251 in DMD and DYNE-101 in DM1.
Initiated Phase 1/2 multiple ascending dose (MAD) clinical trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1).
FDA lifted the clinical hold and cleared its Investigational New Drug (IND) application to initiate its Phase 1/2 MAD clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51.
New in vivo data from DYNE-101 were presented at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting that demonstrated robust knockdown of DMPK RNA in multiple muscles with low monthly dosing in an innovative hTfR1/DMSXL mouse model developed by Dyne and in non-human primates.
Cash, cash equivalents and marketable securities were $291.8 million as of June 30, 2022, which is anticipated to fund operations into the second half of 2024.